Search | IOVS | ARVO Journals

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Clinical Trials October 2015

Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial

PDF

Dennis R. Hoffman; Dianna K. Hughbanks-Wheaton; Rand Spencer; Gary E. Fish; N. Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G. Locke; David G. Birch
TAGS: docosahexaenoic acids, placebos, retinitis pigmentosa, visual fields, x-linked inheritance, visual acuity
Invest. Ophthalmol. Vis. Sci.. 2015; 56(11):6646-6653. https://doi.org/10.1167/iovs.15-17786

ARVO Annual Meeting Abstract June 2015

Ancillary Outcomes of the DHAX Trial: Docosahexaenoic Acid (DHA) Supplementation in X-Linked Retinitis Pigmentosa (XLRP)

Dennis R Hoffman; Dianna K H Wheaton; Rand Spencer; Gary Fish; N Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G Locke; David G Birch

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3803.

Retina August 2014

Safety Assessment of Docosahexaenoic Acid in X-Linked Retinitis Pigmentosa: The 4-Year DHAX Trial

PDF

Dianna K. Hughbanks-Wheaton; David G. Birch; Gary E. Fish; Rand Spencer; N. Shirlene Pearson; Alison Takacs; Dennis R. Hoffman
TAGS: adverse event, docosahexaenoic acids, fatty acids, placebos, plasma, retinitis pigmentosa, safety, x-linked inheritance, blood chemical analysis, lipoproteins
Invest. Ophthalmol. Vis. Sci.. 2014; 55(8):4958-4966. https://doi.org/10.1167/iovs.14-14437

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2014

Safety Assessment of High Dose Docosahexaenoic Acid (DHA) Supplementation in a 4-Year Randomized Clinical Trial in X-linked Retinitis Pigmentosa (XLRP)

Dianna K H Wheaton; David G Birch; Gary E Fish; Rand Spencer; N Shirlene Pearson; Alison Takacs; Robbie Baker; Dennis R Hoffman

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1391.

ARVO Annual Meeting Abstract April 2014

Annual decline in visual sensitivity at the edge of the OCT-defined ellipsoid zone (EZ) in patients with RPGR-mediated x-linked Retinitis Pigmentosa (xlRP)

David G Birch; Kirsten G Locke; Martin Klein; Dianna K H Wheaton; Dennis R Hoffman; Donald C Hood

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1398.

ARVO Annual Meeting Abstract April 2014

High Dose Docosahexaenoic Acid (DHA) Supplementation in X-Linked Retinitis Pigmentosa (XLRP): A 4-Year Randomized, Controlled Clinical Trial

Dennis R Hoffman; Dianna K H Wheaton; Gary E Fish; Rand Spencer; N Shirlene Pearson; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5010.

ARVO Annual Meeting Abstract March 2012

FdOCT Outer Segment Layer (OS) Measures of Progression Over a Two-year Interval in Patients With X-linked Retinitis Pigmentosa (XLRP)

Kirsten G. Locke; Kelly I. Locke; Yuquan Wen; Dennis R. Hoffman; Don C. Hood; David G. Birch

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4573.

ARVO Annual Meeting Abstract March 2012

Perceived Stress And Biochemical Stress In X-linked Retinitis Pigmentosa (XLRP)

Dianna K. Wheaton; Megan Fish; Alison Takacs; Jessica Fernandez; Dennis R. Hoffman

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4588.

ARVO Annual Meeting Abstract April 2011

Assessment of Phenotypic Variability Among Female Carriers of X-linked Retinitis Pigmentosa (xlRP) due to RPGR Mutations

Kaylie D. Webb; Hemaxi M. Patel; Sara J. Bowne; Lori S. Sullivan; Abigail T. Fahim; Stephen P. Daiger; Dennis R. Hoffman; David G. Birch; Dianna K. Wheaton

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4981.

ARVO Annual Meeting Abstract April 2011

FdOCT Measures Of Progression Over A One Year Interval In Patients With X-linked Retinitis Pigmentosa (XLRP)

Kirsten G. Locke; Kelly I. Locke; Yuquan Wen; Donald C. Hood; Dennis R. Hoffman; David G. Birch

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4986.

ARVO Annual Meeting Abstract April 2010

Integrated Systems Approach to Study the Role of Omega-3 Long-Chain Polyunsaturated Fatty Acids in Health and Disease of the Retina

J. P. SanGiovanni; C. M. Aderman; C. Rojas; T. E. Clemons; E. Chew; R. Uauy; D. R. Hoffman; L. E. Smith

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):2774.

ARVO Annual Meeting Abstract April 2009

Evaluation of Olfactory Function in Patients with X-linked Retinitis Pigmentosa (xlRP) Due to Mutations in the Retinitis Pigmentosa GTPase Regulator Gene (RPGR)

D. K. Wheaton; R. K. Koenekoop; H. Khan; A. Takacs; D. R. Hoffman

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):1000.

ARVO Annual Meeting Abstract May 2007

Docosahexaenoic Acid Profiles in Red Blood Cells of Patients With Retinal Degenerative Diseases

D. R. Hoffman; D. K. H. Wheaton; D. G. Birch

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):574.

Retina July 2003

Gene Expression Analysis in Human Fetal Retinal Explants Treated with Docosahexaenoic Acid

PDF

Cecilia V. Rojas; Jessica I. Martínez; Ingrid Flores; Dennis R. Hoffman; Ricardo Uauy
TAGS: docosahexaenoic acids, fatty acids, fetus, gene expression, genes, proteins, rna, messenger, dna, complementary
Invest. Ophthalmol. Vis. Sci.. 2003; 44(7):3170-3177. https://doi.org/10.1167/iovs.02-1138

Articles May 1995

Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa.

PDF

D R Hoffman; D G Birch
TAGS: docosahexaenoic acids, erythrocytes, retinitis pigmentosa, x-linked inheritance
Invest. Ophthalmol. Vis. Sci.. 1995; 36(6):1009-1018.

Articles October 1992

Dietary essential fatty acid supply and visual acuity development.

PDF

E E Birch; D G Birch; D R Hoffman; R Uauy
TAGS: diet, essential fatty acids, fatty acids, visual acuity
Invest. Ophthalmol. Vis. Sci.. 1992; 33(11):3242-3253.

Articles July 1992

Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids.

PDF

D G Birch; E E Birch; D R Hoffman; R D Uauy
TAGS: diet, infant, very low birth weight, omega-3 fatty acids
Invest. Ophthalmol. Vis. Sci.. 1992; 33(8):2365-2376.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial

Ancillary Outcomes of the DHAX Trial: Docosahexaenoic Acid (DHA) Supplementation in X-Linked Retinitis Pigmentosa (XLRP)

Safety Assessment of Docosahexaenoic Acid in X-Linked Retinitis Pigmentosa: The 4-Year DHAX Trial

Safety Assessment of High Dose Docosahexaenoic Acid (DHA) Supplementation in a 4-Year Randomized Clinical Trial in X-linked Retinitis Pigmentosa (XLRP)

Annual decline in visual sensitivity at the edge of the OCT-defined ellipsoid zone (EZ) in patients with RPGR-mediated x-linked Retinitis Pigmentosa (xlRP)

High Dose Docosahexaenoic Acid (DHA) Supplementation in X-Linked Retinitis Pigmentosa (XLRP): A 4-Year Randomized, Controlled Clinical Trial

FdOCT Outer Segment Layer (OS) Measures of Progression Over a Two-year Interval in Patients With X-linked Retinitis Pigmentosa (XLRP)

Perceived Stress And Biochemical Stress In X-linked Retinitis Pigmentosa (XLRP)

Assessment of Phenotypic Variability Among Female Carriers of X-linked Retinitis Pigmentosa (xlRP) due to RPGR Mutations

FdOCT Measures Of Progression Over A One Year Interval In Patients With X-linked Retinitis Pigmentosa (XLRP)

Integrated Systems Approach to Study the Role of Omega-3 Long-Chain Polyunsaturated Fatty Acids in Health and Disease of the Retina

Evaluation of Olfactory Function in Patients with X-linked Retinitis Pigmentosa (xlRP) Due to Mutations in the Retinitis Pigmentosa GTPase Regulator Gene (RPGR)

Docosahexaenoic Acid Profiles in Red Blood Cells of Patients With Retinal Degenerative Diseases

Gene Expression Analysis in Human Fetal Retinal Explants Treated with Docosahexaenoic Acid

Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa.

Dietary essential fatty acid supply and visual acuity development.

Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids.

To View More...

You must be signed into an individual account to use this feature.